KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Gains from Sales and Divestitures: 2018-2019

Historic Gains from Sales and Divestitures for Esperion Therapeutics (ESPR) over the last 2 years, with Dec 2019 value amounting to $17,710.

  • Esperion Therapeutics' Gains from Sales and Divestitures rose 427.95% to $53,587 in Q2 2020 from the same period last year, while for Jun 2020 it was $53,587, marking a year-over-year increase of 427.95%. This contributed to the annual value of $17,710 for FY2019, which is 415.27% up from last year.
  • As of FY2019, Esperion Therapeutics' Gains from Sales and Divestitures stood at $17,710, which was up 415.27% from $3,437 recorded in FY2018.
  • Esperion Therapeutics' 5-year Gains from Sales and Divestitures high stood at $17,710 for FY2019, and its period low was $3,437 during FY2018.
  • Its 2-year average for Gains from Sales and Divestitures is $10,574, with a median of $10,574 in 2018.
  • Data for Esperion Therapeutics' Gains from Sales and Divestitures shows a peak YoY spiked of 415.27% (in 2019) over the last 5 years.
  • Yearly analysis of 2 years shows Esperion Therapeutics' Gains from Sales and Divestitures stood at $3,437 in 2018, then spiked by 415.27% to $17,710 in 2019.